Research programme: antisense RNA inhibitors - Lundbeck/Roche

Drug Profile

Research programme: antisense RNA inhibitors - Lundbeck/Roche

Alternative Names: RNA antagonists - Lundbeck/Roche

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santaris Pharma
  • Developer Lundbeck A/S; Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in Denmark (Parenteral)
  • 16 May 2008 Santaris Pharma receives grant from the Danish National Advanced Technology Foundation for development of RNA antagonists in Neurological disorders
  • 16 May 2008 Early research in Neurological disorders in Denmark (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top